In vitro and in vivo experimental models for drug screening and development for Chagas disease
| Autor: | Gabriela Costa Chaves, André Talvani, Carmenza Spadafora, Egler Chiari, Solange L. de Castro, Maria Terezinha Bahia, Luz Romero, Maria de Nazaré Correia Soeiro, Isabela Ribeiro, Michel Lotrowska, Carlos L. Zani, Bernadette Bourdin, Wim Degrave, Tanya Armstrong, Bianca P. Olivieri, Lucio H. Freitas-Junior, Eric Chatelain, Juan M. Bustamante, Zilton A. Andrade, Sonia G. Andrade, Alvaro J. Romanha, Joseli Lannes-Vieira, Milena Botelho Pereira Soares, José E. Calzada, Bethania Blum |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Microbiology (medical) Drug Chagas disease medicine.medical_specialty lcsh:Arctic medicine. Tropical medicine lcsh:RC955-962 Trypanosoma cruzi media_common.quotation_subject Drug Evaluation Preclinical lcsh:QR1-502 Parasitemia lcsh:Microbiology Mice medicine Animals Chagas Disease drug screening Intensive care medicine Nifurtimox media_common benznidazole business.industry Transmission (medicine) Chagas disease treatment medicine.disease Trypanocidal Agents Clinical trial Disease Models Animal Drug screening Drug development Benznidazole Acute Disease Chronic Disease Immunology Neglected tropical diseases Female business medicine.drug |
| Zdroj: | Scopus-Elsevier Repositório Institucional da UFOP Universidade Federal de Ouro Preto (UFOP) instacron:UFOP Memórias do Instituto Oswaldo Cruz., Vol 105, Iss 2, Pp 233-238 (2010) Memórias do Instituto Oswaldo Cruz, Volume: 105, Issue: 2, Pages: 233-238, Published: MAR 2010 |
| ISSN: | 0074-0276 |
| DOI: | 10.1590/s0074-02762010000200022 |
| Popis: | Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|